Pyridoxal phosphate/Lisinopril

磷酸吡哆醛/赖诺普利

Report date: 2023/11/27 14:59:57

Base Information

Drug NamePyridoxal phosphate/Lisinopril
Drug Alias NameMC-1/Lisinopril赖诺普利/磷酸吡哆醛Lisinopril/MC-1Lisinopril/Pyridoxal phosphateMC- 4232
ClassificationSmall molecules
Mechanisms of ActionPurinergic P2 receptor antagonistsAngiotensin-converting enzyme inhibitors
TargetsPurinergic P2 receptorAngiotensin-converting enzyme
Therapy Area/IndicationsReperfusion InjuryMyocardial Ischemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedicure Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedicure Inc
Active IndicationsN/A
Inactive IndicationsReperfusion InjuryMyocardial Ischemia

Other Information

ATC CodeN/A
Related LinksN/A